Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis.

ABSTRACT:

Background

Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and advanced or metastatic disease remains a major therapeutic challenge. Chromodomain helicase DNA binding protein 1-like (CHD1L) has been implicated as an oncogenic driver in multiple cancer types, yet its role in prostate cancer pathogenesis is not fully defined. The purpose of this study is to investigate the biological significance of CHD1L in prostate cancer and to evaluate the therapeutic potential of its selective inhibitor OTI-611.

Methods

Bioinformatics analyses were conducted to assess the expression, prognostic significance of CHD1L in PCa patients. In vitro, cell viability, cycle progression, apoptosis, and migration/invasion were evaluated using CCK-8, colony formation, fl

SUBMITTER: Hui P 

PROVIDER: S-EPMC12781402 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature